IN BRIEF: Scancell names David Schilansky as interim finance chief
Scancell Holdings PLC - Oxford-based pharmaceutical company focused on cancer immunotherapies - Appoints "highly experienced senior healthcare executive and entrepreneur" David Schilansky, effective immediately, as a financial advisor. Says he will also become interim chief financial officer "later in April". Adds that it has launched a global recruitment process for a permanent successor to current CFO Sath Nirmalananthan, who is leaving Scancell and stepping down from the board with effect from April 24, "to pursue other professional opportunities." Scancell says Schilansky is currently concluding his role as chief executive officer of Ariceum Therapeutics, and starting as a venture partner and entrepreneur-in-residence at Redmile Group. Read More